Evaluation of CD34 antigen expression following tamoxifen as primary treatment for breast cancer.
da Silva
B B
BB
Department of Gynecology, Federal University of Piauí, Teresina, Piauí, Brazil. beneditoborges@globo.com
de Carvalho Gonçalves Nunes Galvão
E R
ER
Dos Santos
L G
LG
D018952:Antigens, CD34 / Q000032:analysis*; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000276:immunology; D018270:Carcinoma, Ductal, Breast / Q000098:blood supply / Q000188:drug therapy* / Q000276:immunology; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D007150:Immunohistochemistry; D009389:Neovascularization, Pathologic / Q000188:drug therapy / Q000276:immunology; D015996:Survival Rate; D013629:Tamoxifen / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome
D018952:Antigens, CD34; D018931:Antineoplastic Agents, Hormonal; D013629:Tamoxifen